NeuroBo Pharmaceuticals Files 8-K

TL;DR

NeuroBo Pharma filed an 8-K on 6/26/24. Nothing major, just standard reporting.

AI Summary

NeuroBo Pharmaceuticals, Inc. filed an 8-K on June 26, 2024, to report other events and financial statements. The company, formerly known as Gemphire Therapeutics Inc. until March 31, 2015, is incorporated in Delaware and headquartered in Cambridge, Massachusetts.

Why It Matters

This filing serves as an official notification of significant corporate events and financial reporting for NeuroBo Pharmaceuticals, Inc.

Risk Assessment

Risk Level: low — The filing is a routine 8-K for reporting events and financial statements, not indicating any immediate material changes or risks.

Key Numbers

• 001-37809 — SEC File Number (Identifies the company's filing with the SEC.)
• 47-2389984 — IRS Employer Identification No. (Company's tax identification number.)

Key Players & Entities

• NeuroBo Pharmaceuticals, Inc. (company) — Registrant
• Gemphire Therapeutics Inc. (company) — Former company name
• June 26, 2024 (date) — Date of report
• March 31, 2015 (date) — Date of former company name change
• 545 Concord Avenue, Suite 210, Cambridge, Massachusetts 02138 (address) — Principal executive offices

FAQ

Key Financial Figures

• $0.001 — ich registered Common Stock, par value $0.001 per share NRBO The Nasdaq Stock Mar

Filing Documents

• nrbo-20240626x8k.htm (8-K) — 46KB
• nrbo-20240626xex99d1.htm (EX-99.1) — 20KB
• nrbo-20240626xex99d2.htm (EX-99.2) — 21KB
• nrbo-20240626x8k001.jpg (GRAPHIC) — 12KB
• nrbo-20240626xex99d1001.jpg (GRAPHIC) — 13KB
• nrbo-20240626xex99d2001.jpg (GRAPHIC) — 13KB
• 0001558370-24-009490.txt ( ) — 285KB
• nrbo-20240626.xsd (EX-101.SCH) — 3KB
• nrbo-20240626_lab.xml (EX-101.LAB) — 16KB
• nrbo-20240626_pre.xml (EX-101.PRE) — 10KB
• nrbo-20240626x8k_htm.xml (XML) — 5KB

01. Other Events

Item 8.01. Other Events. On June 25, 2024, NeuroBo Pharmaceuticals, Inc. (the "Company") issued a press release announcing the closing of its previously announced private placement and registered direct offering. A copy of the press release is filed as Exhibit 99.1 to this Current Report on Form 8-K and incorporated herein by reference. On June 26, 2024, the Company issued a press release announcing the dosing of the first patient in the multiple ascending dose (MAD) Part 2 of its Phase 1 clinical trial of DA-1726, a novel, dual oxyntomodulin (OXM) analog agonist that functions as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR), for the treatment of obesity. A copy of the press release is filed as Exhibit 99.2 to this Current Report on Form 8-K and incorporated herein by reference. Information contained on or accessible through any website reference in the press release is not part of, or incorporated by reference in, this Current Report on Form 8-K, and the inclusion of such website addresses in this Current Report on Form 8-K by incorporation by reference of the press release is as inactive textual references only.

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Exhibit Description 99.1 Press Release dated June 25, 2024. 99.2 Press Release dated June 26, 2024. 104 Cover Page Interactive Data File (embedded within Inline XBRL document).

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. NEUROBO PHARMACEUTICALS, INC. Date: June 26, 2024 By: /s/ Hyung Heon Kim Hyung Heon Kim President and Chief Executive Officer

View Full Filing

View this 8-K filing on SEC EDGAR